RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
Trial details
- Registry ID
- NCT05733611
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRCNCT05733611 | Replimune, Inc. | Phase 2 | Terminated | 2025-08-18Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |